0001209191-15-024177.txt : 20150309 0001209191-15-024177.hdr.sgml : 20150309 20150309173411 ACCESSION NUMBER: 0001209191-15-024177 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150129 FILED AS OF DATE: 20150309 DATE AS OF CHANGE: 20150309 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perkins Adelene Q CENTRAL INDEX KEY: 0001375124 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 15686307 MAIL ADDRESS: STREET 1: C/O INFINITY PHARMACEUTICALS, INC. STREET 2: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2015-01-29 2015-02-02 1 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001375124 Perkins Adelene Q C/O INFINITY PHARMACEUTICALS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 President & CEO Common Stock 2015-01-29 4 S 0 20000 14.8268 D 429432 D The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2014. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.13, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. This amendment is being filed to correct the total amount of securities beneficially owned following the reported transaction. Includes 930 and 967 shares of common stock purchased through participation in the issuer's Employee Stock Purchase Plan on June 30, 2014 and December 31, 2014, respectively. /s/ Adelene Q. Perkins 2015-03-06